KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Ratio (2016 - 2025)

Alnylam Pharmaceuticals' Equity Ratio history spans 17 years, with the latest figure at 0.16 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 904.29% year-over-year to 0.16; the TTM value through Dec 2025 reached 0.16, up 904.29%, while the annual FY2025 figure was 0.16, 904.29% up from the prior year.
  • Equity Ratio reached 0.16 in Q4 2025 per ALNY's latest filing, up from 0.05 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.28 in Q1 2021 to a low of 0.12 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.05, with a median of 0.02 recorded in 2024.
  • Peak YoY movement for Equity Ratio: plummeted 326.94% in 2023, then soared 7274.95% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.16 in 2021, then plummeted by 127.63% to 0.04 in 2022, then dropped by 29.13% to 0.06 in 2023, then surged by 127.46% to 0.02 in 2024, then skyrocketed by 904.29% to 0.16 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Equity Ratio are 0.16 (Q4 2025), 0.05 (Q3 2025), and 0.05 (Q2 2025).